Market capitalization | $1.19b |
Enterprise Value | $1.32b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 432.96 |
EV/Sales (TTM) EV/Sales | 7.78 |
P/S ratio (TTM) P/S ratio | 7.05 |
P/B ratio (TTM) P/B ratio | 20.71 |
Revenue growth (TTM) Revenue growth | 48.15% |
Revenue (TTM) Revenue | $169.14m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
4 Analysts have issued a Harrow Health, Inc. forecast:
4 Analysts have issued a Harrow Health, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 169 169 |
48%
48%
|
|
Gross Profit | 123 123 |
54%
54%
|
|
EBITDA | 4.04 4.04 |
71%
71%
|
EBIT (Operating Income) EBIT | -8.57 -8.57 |
343%
343%
|
Net Profit | -33 -33 |
135%
135%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Harrow Health, Inc. engages in the development, production, and sale of innovative medications. It operates through the Pharmaceutical Compounding and Pharmaceutical Drug Development segments. The Pharmaceutical Compounding segment focuses on the operations of ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.
Head office | United States |
CEO | Mark Baum |
Employees | 315 |
Founded | 2006 |
Website | www.harrow.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.